Pharmacology of visual cycle modulators
US-2020188336-A1 · Jun 18, 2020 · US
Alkoxy compounds for disease treatment
US12029708B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12029708-B2 |
| Application number | US-202217817927-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 5, 2022 |
| Priority date | Oct 5, 2007 |
| Publication date | Jul 9, 2024 |
| Grant date | Jul 9, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating diabetic retinopathy in a subject in need thereof comprising administering to the subject a composition comprising a compound, or stereoisomer, N-oxide or a pharmaceutically acceptable salt thereof, having the structure: 2. The method of claim 1 , wherein the composition is administered to the patient orally. 3. The method of claim 1 , wherein the composition is orally administered to provide the compound in a daily dose of about 2 mg, about 5 mg, about 7 mg, or about 10 mg. 4. The method of claim 1 , wherein the composition comprises (R)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol hydrochloride.
Assignees
Inventors
Classifications
with compounds having aromatic groups, e.g. dipivefrine, ibopamine · CPC title
having aromatic rings, e.g. colchicine, atenolol, progabide · CPC title
having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring · CPC title
the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom · CPC title
containing halogen atoms, or nitro or nitroso groups bound to the carbon skeleton · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12029708B2 cover?
- The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-rela…
- Who is the assignee on this patent?
- Acucela Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/137. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).